- Home
- SOR vs XFOR Comparison
SOR vs XFOR Comparison
Compare SOR & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOR | XFOR |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.4M | 377.3M |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SOR | XFOR |
|---|---|---|
| Price | $45.14 | $2.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.60 |
| AVG Volume (30 Days) | 7.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 150.00 |
| 52 Week Low | $44.20 | $2.80 |
| 52 Week High | $50.41 | $4.83 |
Technical Indicators
Market Signals| Indicator | SOR | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 24.87 |
| Support Level | $45.02 | $2.83 |
| Resistance Level | $47.24 | $4.45 |
| Average True Range (ATR) | 0.76 | 0.18 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 34.80 | 8.88 |
Price Performance
Historical ComparisonAbout SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.